Efficacy of Neoadjuvant Single or Dual Anti-HER-2 Therapy Combined with Chemotherapy in Patients with HER-2-Positive Breast Cancer: A Single-Center Retrospective Study.

BACKGROUND: Studies have shown that neoadjuvant anti-HER-2 therapy and chemotherapy can increase pathologic complete response (pCR) rate in HER-2-positive breast cancer patients and improve prognosis. However, data from Chinese patients are limited. Therefore, we conducted a single-center retrospective study to evaluate the effects of neoadjuvant single or dual anti-HER-2 therapy and chemotherapy in Chinese HER-2-positive breast cancer patients and to explore the prognostic indicators of pCR and progression-free survival (PFS). METHODS: We included patients with HER-2-positive breast cancer treated with neoadjuvant anti-HER-2 therapy and chemotherapy at the First Affiliated Hospital of Chongqing Medical University in China from January 2016 to July 2020. We analyzed the relationship between patient characteristics and the pCR rate or PFS. RESULTS: Forty-seven patients with HER-2-positive breast cancer receiving neoadjuvant anti-HER-2 therapy and chemotherapy were included. Univariate analysis suggested that compared with patients receiving neoadjuvant single anti-HER-2 therapy, patients receiving neoadjuvant dual anti-HER-2 therapy tended to have a higher pCR rate and better PFS. Patients who achieved pCR also tended to have longer PFS. Multivariate analysis indicated that patients with greater systemic inflammation response index (SIRI) reduction (>0.54) during neoadjuvant treatment (NAT) and patients with a lower T stage were more likely to achieve pCR. Patients aged ≤60 years with lower Ki-67 had longer PFS. CONCLUSION: Greater SIRI reduction during NAT was an independent influencing factor for pCR. Patients receiving neoadjuvant dual anti-HER-2 therapy and chemotherapy tended to have higher pCR rates and longer PFS. Patients who achieved pCR also tended to have longer PFS.

[Therapeutic effects of C-erbB-2 and C-raf-1 gene combined with antisense oligodeoxynucleotide on the human ovarian carcinoma transplanted subcutaneously in nude mice].

BACKGROUND & OBJECTIVE: Although many positive studies were reported on single C-erbB-2 or C-raf-1 antisense oligodeoxynucleo- tide (ASODN) in cancer treatment, these studies were usually limited in single gene or in cell level and were not appropriate according to the multiple genes hypotheses of tumorigenesis. This study was designed to investigate the effects of C-erbB-2 and C-raf-1 combined with ASODN on the treatment of ovarian carcinoma xenograft in nude mice. METHODS: The model of xenografts derived from ovarian epithelial cancer SKOV3 cells was established in Balb/C nude mice, then they were randomly divided into a negative control group and 6 experimental groups [intraperitoneal injection of (1)liposome-C-erbB-2-ASODN, (2)liposome- C-raf-1-ASODN, (3)liposome-C-erbB-2-ASODN, (4)liposome-C-raf-1-ASODN, (5)whole-dose combined ASODN, (6)half-dose combined ASODN. The weight of nude mice and tumor volume were measured. The tumor growth inhibitory rates and the tumor volume decreased rates were calculated. RESULTS: C-erbB-2 and C-raf-1 combined with ASODN exhibited potent tumor growth inhibition. The tumor volume inhibitory rates were 72.5% and 78.4%; the tumor weight inhibitory rates were 70.7% and 75.3%; the tumor volume decreased rates were 29.7% and 41.6% for whole-dose combined group and half-dose combined group post-experiment, respectively. Of the 7 groups, there was no significant difference on nude mice weight post-experiment and therefore the toxicity was endurable. CONCLUSION: C-erbB-2 and C-raf-1 combined with ASODN showed potent tumor growth inhibition in vivo.

[Inhibition effects of c-erbB-2 and c-raf-1 antisense oligodeoxynucleotides combined transfection on the human ovarian carcinoma transplanted subcutaneously in nude mice].

OBJECTIVE: To investigate the inhibition effects of c-erbB-2 and c-raf-1 antisense oligodeoxynucleotides (ASODN) combined transfection on the human ovarian epithelial cancer transplanted subcutaneously in nude mice. METHODS: There were 7 groups: normal control group, c-erbB-2 sense observed group, c-raf-1 sense observed group, c-erbB-2 antisense observed group, c-raf-1 antisense observed group, whole dose combined group, half dose combined group. Human ovarian epithelial cancer cells SKOV3 were treated by different oligodeoxynucleotides, then transplanted subcutaneously in nude mice, respectively. The changes of tumor volume were observed and the tumor growth inhibitory rate was calculated. RESULTS: There was no difference between sense observed group and normal control group. There was a larger growth inhibitory rate in whole -dose combined group and half -dose combined group, the first time that can be detected was 13.7 days and 15.2 days, and the maximum tumor growth inhibitory rates were 61.1% and 71.3%, respectively. CONCLUSIONS: The results suggested that ASODN combined transfection can inhibit the tumorigenesis of ovarian epithelial cancer cells in nude mice, it may be a more useful gene therapy for the ovarian epithelial carcinoma.